EP Patent

EP1463733A2 — Mitotic kinesin inhibitors

Assigned to Merck and Co Inc · Expires 2004-10-06 · 22y expired

What this patent protects

The present invention relates to thienopyrimidinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these…

USPTO Abstract

The present invention relates to thienopyrimidinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.

Drugs covered by this patent

Patent Metadata

Patent number: EP1463733A2
Jurisdiction: EP
Classification: —
Expires: 2004-10-06
Drug substance claim: No
Drug product claim: No
Assignee: Merck and Co Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.